AVROBIO

$14.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.21%) Today
$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, and ETFs commission-free!

About AVRO

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA. The listed name for AVRO is AVROBIO, Inc. Common Stock.

CEO
Geoff MacKay
Employees
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
511.41M
Price-Earnings Ratio
Dividend Yield
Average Volume
508.60K
High Today
$14.23
Low Today
$13.81
Open Price
$14.08
Volume
322.61K
52 Week High
$29.32
52 Week Low
$9.76

Collections

AVRO Earnings

-$1.01
-$0.67
-$0.34
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 15, Pre-Market

You May Also Like